SETD7 and benign neoplasm: Montenegro et al. compared SETD7 mRNA levels from 87 samples (77 invasive ductal or lobular carcinomas and 10 benign tumours; all females) and found significantly higher SETD7 in benign tumours or in tumours that had pathological complete remission, while low SETD7 mRNA was significantly correlated with reduced overall survival (OS) and disease-free survival (DFS) independently of the tumours’ primary staging and therapy [36].